Longitudinal Effectiveness and Laboratory Safety Profile of Janus Kinase Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World Study

Background/Objectives: Janus kinase inhibitors (JAKis) are effective treatments for moderate-to-severe atopic dermatitis (AD), although longitudinal real-world data on their laboratory safety profile remain limited and there is scarce information regarding whether laboratory changes differ according to JAKi use. So, the main objective of this study was to evaluate longitudinal laboratory changes in patients with AD treated with JAKis in routine clinical practice and to evaluate these changes across different types of JAKis. Methods: We conducted a retrospective observational study including patients with moderate-to-severe AD who initiated treatment with abrocitinib, upadacitinib, or baricitinib. Demographic, clinical, laboratory, and patient-reported outcome data were collected at baseline and after 4, 12–16, 24–32, and 48–52 weeks. Longitudinal changes were analyzed using REML mixed-effects models with categorical visit and a patient-specific random intercept, using logarithmic transformations for skewed laboratory parameters. Results: Forty-three patients were included. EASI decreased from 21.18 ± 8.82 at baseline to 6.06 ± 8.27 at week 4 and 7.85 ± 8.63 at weeks 48–52, while pruritus NRS decreased from 7.15 ± 2.48 to 2.23 ± 2.78 and 4.34 ± 3.28, respectively (p < 0.001). At weeks 24–32, total cholesterol (+29.26), LDL cholesterol (+16.09), HDL cholesterol (+6.57), and MCV (+2.12) increased significantly, whereas CRP (−2.87), leukocyte (−1.07), and neutrophil counts (−1.07) decreased significantly. Mean creatinine changes were small. No significant longitudinal changes were observed in AST, ALT, triglycerides or hemoglobin. Few between-treatment differences were identified. No MACE, VTE or changes in lipid-lowering treatment were documented during recorded follow-up. Conclusions: JAKis provided substantial clinical benefit with a favorable longitudinal laboratory safety profile. Laboratory abnormalities were generally mild and consistent with the known safety profile of this class.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2026-11-13
DOI
https://doi.org/10.3390/pharmaceutics18111473
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Longitudinal Effectiveness and Laboratory Safety Profile of Janus Kinase Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World Study

Salvador Arias‐Santiago, Trinidad Montero‐Vílchez, Marta Elosua‐González, C Montero-Vilchez et al.
2 links
Pharmaceutics
Dermatology and Skin Diseases
article

Longitudinal Effectiveness and Laboratory Safety Profile of Janus Kinase Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World Study

Salvador Arias‐Santiago, Trinidad Montero‐Vílchez, Marta Elosua‐González, C Montero-Vilchez, Alberto Ruiz-Jiménez
article en

Abstract

Background/Objectives: Janus kinase inhibitors (JAKis) are effective treatments for moderate-to-severe atopic dermatitis (AD), although longitudinal real-world data on their laboratory safety profile remain limited and there is scarce information regarding whether laboratory changes differ according to JAKi use. So, the main objective of this study was to evaluate longitudinal laboratory changes in patients with AD treated with JAKis in routine clinical practice and to evaluate these changes across different types of JAKis. Methods: We conducted a retrospective observational study including patients with moderate-to-severe AD who initiated treatment with abrocitinib, upadacitinib, or baricitinib. Demographic, clinical, laboratory, and patient-reported outcome data were collected at baseline and after 4, 12–16, 24–32, and 48–52 weeks. Longitudinal changes were analyzed using REML mixed-effects models with categorical visit and a patient-specific random intercept, using logarithmic transformations for skewed laboratory parameters. Results: Forty-three patients were included. EASI decreased from 21.18 ± 8.82 at baseline to 6.06 ± 8.27 at week 4 and 7.85 ± 8.63 at weeks 48–52, while pruritus NRS decreased from 7.15 ± 2.48 to 2.23 ± 2.78 and 4.34 ± 3.28, respectively (p < 0.001). At weeks 24–32, total cholesterol (+29.26), LDL cholesterol (+16.09), HDL cholesterol (+6.57), and MCV (+2.12) increased significantly, whereas CRP (−2.87), leukocyte (−1.07), and neutrophil counts (−1.07) decreased significantly. Mean creatinine changes were small. No significant longitudinal changes were observed in AST, ALT, triglycerides or hemoglobin. Few between-treatment differences were identified. No MACE, VTE or changes in lipid-lowering treatment were documented during recorded follow-up. Conclusions: JAKis provided substantial clinical benefit with a favorable longitudinal laboratory safety profile. Laboratory abnormalities were generally mild and consistent with the known safety profile of this class.

PharmaceuticsVol. 18(11)
Universidad de Granada (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Instituto de Investigación Biosanitaria de Granada (ES), Hospital Universitario Virgen de las Nieves (ES)
Instituto de Salud Carlos III
Good health and well-being
Dermatology and Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon